-
Je něco špatně v tomto záznamu ?
Inhibition of human anthracycline reductases by emodin - A possible remedy for anthracycline resistance
J. Hintzpeter, JM. Seliger, J. Hofman, HJ. Martin, V. Wsol, E. Maser,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- anthrachinony farmakologie MeSH
- antibiotika antitumorózní farmakologie MeSH
- chemorezistence účinky léků MeSH
- daunomycin farmakologie MeSH
- emodin farmakologie MeSH
- inhibitory proteinkinas farmakologie MeSH
- lidé MeSH
- nádorové buněčné linie MeSH
- oxidoreduktasy antagonisté a inhibitory metabolismus MeSH
- simulace molekulového dockingu MeSH
- synergismus léků MeSH
- viabilita buněk účinky léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
The clinical application of anthracyclines, like daunorubicin and doxorubicin, is limited by two factors: dose-related cardiotoxicity and drug resistance. Both have been linked to reductive metabolism of the parent drug to their metabolites daunorubicinol and doxorubicinol, respectively. These metabolites show significantly less anti-neoplastic properties as their parent drugs and accumulate in cardiac tissue leading to chronic cardiotoxicity. Therefore, we aimed to identify novel and potent natural inhibitors for anthracycline reductases, which enhance the anticancer effect of anthracyclines by preventing the development of anthracycline resistance. Human enzymes responsible for the reductive metabolism of daunorubicin were tested for their sensitivity towards anthrachinones, in particular emodin and anthraflavic acid. Intense inhibition kinetic data for the most effective daunorubicin reductases, including IC50- and Ki-values, the mode of inhibition, as well as molecular docking, were compiled. Subsequently, a cytotoxicity profile and the ability of emodin to reverse daunorubicin resistance were determined using multiresistant A549 lung cancer and HepG2 liver cancer cells. Emodin potently inhibited the four main human daunorubicin reductases in vitro. Further, we could demonstrate that emodin is able to synergistically sensitize human cancer cells towards daunorubicin at clinically relevant concentrations. Therefore, emodin may yield the potential to enhance the therapeutic effectiveness of anthracyclines by preventing anthracycline resistance via inhibition of the anthracycline reductases. In symphony with its known pharmacological properties, emodin might be a compound of particular interest in the management of anthracycline chemotherapy efficacy and their adverse effects.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16020014
- 003
- CZ-PrNML
- 005
- 20160809111019.0
- 007
- ta
- 008
- 160722s2016 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.taap.2016.01.003 $2 doi
- 024 7_
- $a 10.1016/j.taap.2016.01.003 $2 doi
- 035 __
- $a (PubMed)26773812
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Hintzpeter, Jan $u Institute of Toxicology and Pharmacology for Natural Scientists, University Medical School Schleswig-Holstein, Campus Kiel, Brunswiker Str. 10, 24105 Kiel, Germany. Electronic address: hintzpeter@toxi.uni-kiel.de.
- 245 10
- $a Inhibition of human anthracycline reductases by emodin - A possible remedy for anthracycline resistance / $c J. Hintzpeter, JM. Seliger, J. Hofman, HJ. Martin, V. Wsol, E. Maser,
- 520 9_
- $a The clinical application of anthracyclines, like daunorubicin and doxorubicin, is limited by two factors: dose-related cardiotoxicity and drug resistance. Both have been linked to reductive metabolism of the parent drug to their metabolites daunorubicinol and doxorubicinol, respectively. These metabolites show significantly less anti-neoplastic properties as their parent drugs and accumulate in cardiac tissue leading to chronic cardiotoxicity. Therefore, we aimed to identify novel and potent natural inhibitors for anthracycline reductases, which enhance the anticancer effect of anthracyclines by preventing the development of anthracycline resistance. Human enzymes responsible for the reductive metabolism of daunorubicin were tested for their sensitivity towards anthrachinones, in particular emodin and anthraflavic acid. Intense inhibition kinetic data for the most effective daunorubicin reductases, including IC50- and Ki-values, the mode of inhibition, as well as molecular docking, were compiled. Subsequently, a cytotoxicity profile and the ability of emodin to reverse daunorubicin resistance were determined using multiresistant A549 lung cancer and HepG2 liver cancer cells. Emodin potently inhibited the four main human daunorubicin reductases in vitro. Further, we could demonstrate that emodin is able to synergistically sensitize human cancer cells towards daunorubicin at clinically relevant concentrations. Therefore, emodin may yield the potential to enhance the therapeutic effectiveness of anthracyclines by preventing anthracycline resistance via inhibition of the anthracycline reductases. In symphony with its known pharmacological properties, emodin might be a compound of particular interest in the management of anthracycline chemotherapy efficacy and their adverse effects.
- 650 _2
- $a anthrachinony $x farmakologie $7 D000880
- 650 _2
- $a antibiotika antitumorózní $x farmakologie $7 D000903
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a viabilita buněk $x účinky léků $7 D002470
- 650 _2
- $a daunomycin $x farmakologie $7 D003630
- 650 _2
- $a chemorezistence $x účinky léků $7 D019008
- 650 _2
- $a synergismus léků $7 D004357
- 650 _2
- $a emodin $x farmakologie $7 D004642
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a simulace molekulového dockingu $7 D062105
- 650 _2
- $a oxidoreduktasy $x antagonisté a inhibitory $x metabolismus $7 D010088
- 650 _2
- $a inhibitory proteinkinas $x farmakologie $7 D047428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Seliger, Jan Moritz $u Institute of Toxicology and Pharmacology for Natural Scientists, University Medical School Schleswig-Holstein, Campus Kiel, Brunswiker Str. 10, 24105 Kiel, Germany.
- 700 1_
- $a Hofman, Jakub $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic.
- 700 1_
- $a Martin, Hans-Joerg $u Institute of Toxicology and Pharmacology for Natural Scientists, University Medical School Schleswig-Holstein, Campus Kiel, Brunswiker Str. 10, 24105 Kiel, Germany.
- 700 1_
- $a Wsol, Vladimir $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic.
- 700 1_
- $a Maser, Edmund $u Institute of Toxicology and Pharmacology for Natural Scientists, University Medical School Schleswig-Holstein, Campus Kiel, Brunswiker Str. 10, 24105 Kiel, Germany.
- 773 0_
- $w MED00010691 $t Toxicology and applied pharmacology $x 1096-0333 $g Roč. 293, č. - (2016), s. 21-9
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26773812 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160722 $b ABA008
- 991 __
- $a 20160809111256 $b ABA008
- 999 __
- $a ok $b bmc $g 1154684 $s 944542
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 293 $c - $d 21-9 $e 20160107 $i 1096-0333 $m Toxicology and applied pharmacology $n Toxicol Appl Pharmacol $x MED00010691
- LZP __
- $a Pubmed-20160722